...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Akt1 rs2498801 Is Related to Survival in Head and Neck Squamous Cell Cancer Treated with Radiotherapy
【24h】

Akt1 rs2498801 Is Related to Survival in Head and Neck Squamous Cell Cancer Treated with Radiotherapy

机译：Akt1 rs2498801与放射疗法治疗的头颈部鳞状细胞癌的存活率有关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Radiotherapy (RT) with or without chemotherapy (CT) plays an important role as exclusive treatment in patients with head and neck squamous cell cancer (HNSCC). Unfortunately, in some cases, benefit for patients is not recorded and only treatment-related complications are registered. Materials and Methods: Data relating to Akt1 single nucleotide polymorphism (SNP) and response to treatment of 46 patients treated with exclusive RT or RT-CT for HNSCC were evaluated. Results: For heterozygous patients median overall survival was 28.5 months, while for the wildtype group median overall survival was 10.9 (p=0.019). Three-year survival was 85% for mutated Akt1 homozygosis and 40% for patients with a heterozygous status (p=0.019, hazard ratio (HR)=7.960). Conclusion: SNP of rs2498804 can recognize patients resistant to RT-CT. Further studies are needed to confirm our data and to investigate the role of Akt SNPs in HNSCC patients.
机译：背景：放疗（RT）或不伴化疗（CT）在头颈部鳞状细胞癌（HNSCC）患者中作为独家治疗起着重要作用。不幸的是，在某些情况下，没有记录对患者的益处，仅记录了与治疗有关的并发症。材料和方法：评估与Akt1单核苷酸多态性（SNP）有关的数据以及46例接受HNSCC独家RT或RT-CT治疗的患者的治疗反应。结果：对于杂合性患者，中位总生存期为28.5个月，而对于野生型组，中位总生存期为10.9（p = 0.019）。突变的Akt1纯合子的三年生存率为85％，具有杂合状态的患者为40％（p = 0.019，危险比（HR）= 7.960）。结论：rs2498804的SNP可识别对RT-CT有抗药性的患者。需要进一步的研究来确认我们的数据并调查Akt SNP在HNSCC患者中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号